Literature DB >> 10623463

HsRec2/Rad51L1, a protein influencing cell cycle progression, has protein kinase activity.

P A Havre1, M Rice, R Ramos, E B Kmiec.   

Abstract

Human Rec2/Rad51L1 is a member of the Rad51 family of proteins. Although recombinase activity, typical of this family, could not be established, its overexpression in mammalian cells has been shown to cause a delay in G1. Moreover, since hsRec2/Rad51L1 has been found to be induced by both ionizing and UV irradiation, it is likely that hsRec2/Rad51L1 is elevated following any DNA damage and causes a G1 delay to allow time for DNA repair to occur. Limited homology with catalytic domains X and XI of protein kinase A suggested that kemptide, an artificial substrate containing one phosphorylatable residue, a serine, might serve as a substrate for hsRec2/Rad51L1. Here, we report that hsRec2/Rad51L1 can phosphorylate kemptide, as well as myelin basic protein, p53, cyclin E, and cdk2, but not a peptide substrate containing tyrosine only. The finding that hsRec2/Rad51L1 exhibits protein kinase activity is a first step toward identifying a mechanism whereby this protein affects the cell cycle. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10623463     DOI: 10.1006/excr.1999.4725

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  10 in total

1.  Complex formation by the human RAD51C and XRCC3 recombination repair proteins.

Authors:  J Y Masson; A Z Stasiak; A Stasiak; F E Benson; S C West
Journal:  Proc Natl Acad Sci U S A       Date:  2001-07-17       Impact factor: 11.205

2.  A molecular portrait of Arabidopsis meiosis.

Authors:  Hong Ma
Journal:  Arabidopsis Book       Date:  2006-06-06

3.  The transition from conjugal development to the first vegetative cell division is dependent on RAD51 expression in the ciliate Tetrahymena thermophila.

Authors:  T C Marsh; E S Cole; D P Romero
Journal:  Genetics       Date:  2001-04       Impact factor: 4.562

4.  Gamma-radiation sensitivity and polymorphisms in RAD51L1 modulate glioma risk.

Authors:  Yanhong Liu; Sanjay Shete; Li-E Wang; Randa El-Zein; Carol J Etzel; Fu-Wen Liang; Georgina Armstrong; Spyros Tsavachidis; Mark R Gilbert; Kenneth D Aldape; Jinliang Xing; Xifeng Wu; Qingyi Wei; Melissa L Bondy
Journal:  Carcinogenesis       Date:  2010-07-07       Impact factor: 4.944

5.  Disruption of muREC2/RAD51L1 in mice results in early embryonic lethality which can Be partially rescued in a p53(-/-) background.

Authors:  Z Shu; S Smith; L Wang; M C Rice; E B Kmiec
Journal:  Mol Cell Biol       Date:  1999-12       Impact factor: 4.272

6.  A truncating variant of RAD51B associated with primary ovarian insufficiency provides insights into its meiotic and somatic functions.

Authors:  Monica M Franca; Yazmine B Condezo; Maëva Elzaiat; Natalia Felipe-Medina; Fernando Sánchez-Sáez; Sergio Muñoz; Raquel Sainz-Urruela; M Rosario Martín-Hervás; Rodrigo García-Valiente; Manuel A Sánchez-Martín; Aurora Astudillo; Juan Mendez; Elena Llano; Reiner A Veitia; Berenice B Mendonca; Alberto M Pendás
Journal:  Cell Death Differ       Date:  2022-05-27       Impact factor: 15.828

7.  Overexpression of Drosophila Rad51 protein (DmRad51) disrupts cell cycle progression and leads to apoptosis.

Authors:  Siuk Yoo; Bruce D McKee
Journal:  Chromosoma       Date:  2004-07-15       Impact factor: 4.316

8.  A miR-590/Acvr2a/Rad51b axis regulates DNA damage repair during mESC proliferation.

Authors:  Qidong Liu; Guiying Wang; Yafang Chen; Guoping Li; Dandan Yang; Jiuhong Kang
Journal:  Stem Cell Reports       Date:  2014-11-20       Impact factor: 7.765

9.  Genome expression profiling predicts the molecular mechanism of peripheral myelination.

Authors:  Xiaoming Wu
Journal:  Int J Mol Med       Date:  2017-12-22       Impact factor: 4.101

Review 10.  Etiology and pathogenesis of uterine leiomyomas: a review.

Authors:  Gordon P Flake; Janet Andersen; Darlene Dixon
Journal:  Environ Health Perspect       Date:  2003-06       Impact factor: 9.031

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.